Biogen confirms second PML case among Tecfidera patients

When the FDA added information about progressive multifocal leukoencephalopathy (PML) to the label of Biogen's Tecfidera last year, only one patient on the oral MS-fighter had developed the rare brain disease. Now, the Massachusetts company has confirmed another case, though this one--unlike the last--was nonfatal, a spokeswoman told MedPage Today. Story | More